<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380808</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan BR2011-05</org_study_id>
    <nct_id>NCT01380808</nct_id>
  </id_info>
  <brief_title>Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)</brief_title>
  <official_title>A Phase II Study of Capecitabine and Pseudomonas Aeruginosa Combination in the Salvage Treatment of Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The progression free survival could be prolonged adding pseudomonas aeruginosa to monotherapy
      capecitabine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the efficacy of the combination is much better than monotherapy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capecitabine and pseudomonas aeruginosa combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine and pseudomonas aeruginosa combination</intervention_name>
    <description>capecitabine 1000mg/m2 bid, po. pseudomonas aeruginosa 0.5ml loading dose,1ml qod ih.</description>
    <arm_group_label>experimental arm</arm_group_label>
    <other_name>capecitabine</other_name>
    <other_name>pseudonomas aeruginosa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female between 18 and 70 years old

          2. Patients with histologic proved metastatic breast cancer, unsuitable to be treated
             locally.

          3. Patients with Her-2 negative breast cancer(HER-2 negative or one plus by IHC test , if
             HER-2 two plus by IHC,FISH result should be negative)

          4. Disease progression after anthracycline and/or taxane regimen therapy and candidate
             for capecitabine monotherapy

          5. Patients previously treated by capecitabine containing regimen should response to the
             chemotherapy containing capecitabine and progressed at least 4 months after the last
             capecitabine treatment

          6. Karnofsky score more than 70；ECOG 0~2；

          7. Normal functions with heart, liver,renal and bone marrow

          8. WBC≥4×109/L；Hb≥90 g/L；plt≥100×109/L

          9. Got ICF before enrollment

        Exclusion Criteria:

          1. Pregnant or breast-feeding women or positive serum pregnancy test

          2. Uncontrolled brain metastases. Patients with brain metastases must be locally treated
             and the disease must be stable for at least one month at the time of enrolling

          3. Participation in any investigational drug study within 4 weeks preceding treatment
             start.

          4. Concurrent other malignancy at other sites or previous other cancer within the last 5
             years, with the exception of adequately treated in situ carcinoma of cervix uteri or
             basal or squamous cell carcinoma of the skin or a contralateral breast cancer.

          5. Serious uncontrolled intercurrent infections

          6. Poor compliance
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xichun Hu, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>July 25, 2013</last_update_submitted>
  <last_update_submitted_qc>July 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

